Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-037 in subjects with elevated blood uric acid levels
NCT02464605Phase 1Completed
- Sponsor
- Selecta Biosciences
- Start
- May 2015
- Primary completion
- Nov 2015
- Modality
- Therapeutic Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegadricase in hyperuricemia and gout, sponsored by Selecta Biosciences. Primary endpoint: Safety and tolerability as assessed by frequency of drug related adverse events at 30 days. Started May 2015; status: completed.
02
Drugs
pegadricase
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02464605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464605.